Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009, Article ID 937305, 9 pages
http://dx.doi.org/10.1155/2009/937305
Review Article

Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA

Received 28 April 2009; Accepted 3 September 2009

Academic Editor: Michael A. Carducci

Copyright © 2009 John L. Marshall. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [17 citations]

The following is the list of published articles that have cited the current article.

  • Gernot Kriegshuser, Veronika Auner, and Robert Zeillinger, “New and potential clinical applications of KRAS as a cancer biomarker,” Expert Opinion on Medical Diagnostics, vol. 4, no. 5, pp. 383–395, 2010. View at Publisher · View at Google Scholar
  • Erlinda M. Gordon, and Frederick L. Hall, “Noteworthy clinical case studies in cancer gene therapy: Tumor-targeted Rexin-G advances as an efficacious anti-cancer agent,” International Journal Of Oncology, vol. 36, no. 6, pp. 1341–1353, 2010. View at Publisher · View at Google Scholar
  • Erlinda M. Gordon, and Frederick L. Hall, “Noteworthy clinical case studies in cancer gene therapy: Tumortargeted rexin-G advances as an efficacious anti-cancer agent,” International Journal of Oncology, vol. 36, no. 6, pp. 1341–1353, 2010. View at Publisher · View at Google Scholar
  • Sreeparna Banerjee, and Hernan Flores-Rozas, “Monoclonal antibodies for targeted therapy in colorectal cancer,” Cancer Biology & Therapy, vol. 9, no. 8, pp. 563–571, 2010. View at Publisher · View at Google Scholar
  • Raffaele Addeo, Michele Caraglia, Domenico Cerbone, Nicola Frega, Gaetano Cimmino, Alberto Abbruzzese, and Salvatore Del Prete, “Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer,” Expert Review of Anticancer Therapy, vol. 10, no. 4, pp. 499–505, 2010. View at Publisher · View at Google Scholar
  • Gillian M. Keating, “Panitumumab: A review of its use in metastatic colorectal cancer,” Drugs, vol. 70, no. 8, pp. 1059–1078, 2010. View at Publisher · View at Google Scholar
  • Ana R. Quesada, Miguel Ángel Medina, Ramón Muñoz-Chápuli, and Ángel Luis G. Ponce, “Do not say ever never more: The ins and outs of antiangiogenic therapies,” Current Pharmaceutical Design, vol. 16, no. 35, pp. 3932–3957, 2010. View at Publisher · View at Google Scholar
  • Ezzeldin M. Ibrahim, and Khaled M. Abouelkhair, “Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials,” Medical Oncology, vol. 28, pp. S310–S317, 2011. View at Publisher · View at Google Scholar
  • Howard Burris, Joe Stephenson, Gregory A. Otterson, Mark Stein, Jesse McGreivy, Yu-Nien Sun, Megan Ingram, Yining Ye, and Lee S. Schwartzberg, “Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer,” Journal of Oncology, vol. 2011, pp. 1–11, 2011. View at Publisher · View at Google Scholar
  • K. Bouzid, N. Bedairia, and M. Marty, “Therapeutic monoclonal antibodies in oncology,” Pathologie Biologie, vol. 60, no. 4, pp. 223–228, 2012. View at Publisher · View at Google Scholar
  • G. W. Prager, and M. Poettler, “Angiogenesis in cancer Basic mechanisms and therapeutic advances,” Hamostaseologie, vol. 32, no. 2, pp. 105–+, 2012. View at Publisher · View at Google Scholar
  • Marc Peeters, Allen Cohn, Claus-Henning Köhne, and Jean-Yves Douillard, “Panitumumab in Combination With Cytotoxic Chemotherapy for the Treatment of Metastatic Colorectal Carcinoma,” Clinical Colorectal Cancer, vol. 11, no. 1, pp. 14–23, 2012. View at Publisher · View at Google Scholar
  • Efrat Dotan, Judi Sylvester, Steven J. Cohen, Neal J. Meropol, Barbara Burtness, Crystal S. Denlinger, James Lee, David Mintzer, Fang Zhu, Karen Ruth, and Holly Tuttle, “A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A fox chase extramural research study,” Journal of Gastrointestinal Cancer, vol. 43, no. 4, pp. 562–569, 2012. View at Publisher · View at Google Scholar
  • Martine Piccart, “Personalised cancer management: Closer, but not here yet,” Annals of Oncology, vol. 24, no. 8, pp. 1951–1955, 2013. View at Publisher · View at Google Scholar
  • Giuseppe Aprile, Stefania Eufemia Lutrino, Laura Ferrari, Mariaelena Casagrande, Marta Bonotto, Elena Ongaro, and Fabio Puglisi, “Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients,” World Journal of Gastroenterology, vol. 19, no. 46, pp. 8474–8488, 2013. View at Publisher · View at Google Scholar
  • Teng Ma, Hao Liu, Xianlei Sun, Liquan Gao, Jiyun Shi, Huiyun Zhao, Bing Jia, Fan Wang, and Zhaofei Liu, “Serial in Vivo Imaging Using a Fluorescence Probe Allows Identification of Tumor Early Response to Cetuximab Immunotherapy,” Molecular Pharmaceutics, vol. 12, no. 1, pp. 10–17, 2015. View at Publisher · View at Google Scholar
  • L. Faugeras, A. Dili, A. Druez, B. Krug, C. Decoster, and L. D’Hondt, “Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy,” Critical Reviews in Oncology/Hematology, vol. 115, pp. 59–66, 2017. View at Publisher · View at Google Scholar